Neurizon Therapeutics Limited has released a press release.
Phase II trial prelim results demonstrate clinical benefit
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- New patent granted for non-cancer applications
- PharmAust secures core China patent
- Appendix 4C - Quarterly Report & Company Update - March 2017
- Dr Richard Hopkins Appointed as CEO of PharmAust
- Appendix 4D & Financial Report - Dec 2016
Later from Neurizon Therapeutics
- PharmAust secures core patent in Japan
- New European patent granted for non-cancer applications
- Canadian-based specialists to reformulate monepantel
- Epichem reports record $3m revenues & expands laboratory
- PharmAust Shareholders Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics